New London Bridge research facility to capitalise on Gov’s life science focus
One of the UK’s biggest early-phase clinical trials institutes has cut the ribbon on a new research facility in London that will capitalise on the Government’s renewed focus on life sciences as part of its recently announced Industrial Strategy.
Richmond Pharmacology, which has been conducting clinical trials since 2001, has opened its new research facility in London Bridge in an effort to cement the UK’s position as European leader in phase I clinical studies.
It said the new facility will help to support hospitals and universities work on the development and design of innovative new medicines in ‘crucial disease areas’, helping them to attract and retain the world’s best life sciences talent in the process.
Dr Jorg Taubel, Chief Executive Officer of Richmond Pharmacology said the new research facility was part of the firm’s ‘continued commitment’ to making the UK and London a ‘world-leading centre’ for medical and drug-related research.
He commented: “This is an exciting time for Richmond Pharmacology and we are looking forward to continuing our work in supporting the development of ground-breaking medicines and therapies, whilst also having access to and working alongside some of the best global talent in clinical research.”
Currently, the life sciences sector contributes over £60bn to the UK economy and was identified as one of the central areas of focus for the Government’s Industrial Strategy, which was unveiled in January.
With significant new investment and sector-specific deals predicted over the coming years, the new Richmond facility will be looking to plug into the thriving UK ecosystem of life science companies and research.
Sarah Haywood, who is Chief Executive Officer of Med City UK, said the new research facility would be ideally situated to take advantage of London’s diverse, metropolitan population which opens up opportunities for wide-ranging trials.
She said: “Clinical trials are an essential part of the process to bring new healthcare products to patients. London and the UK offers an ideal location for clinical studies.
“London, with 8.3 million NHS patients, a third of which were born overseas, provides an excellent platform for clinical research organisations like Richmond Pharmacology.”
Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →
Enjoy the read? Get Bdaily delivered.
Sign up to receive our popular morning London email for free.